Alzheimer's failure raises questions about disease-modifying strategies.
Extance
Andy
A
D000409:Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000201:enzymology* / Q000628:therapy*; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D001381:Azepines / Q000494:pharmacology / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic / Q000639:trends*; D004345:Drug Industry / Q000639:trends; D006801:Humans; D012878:Skin Neoplasms / Q000139:chemically induced; D017211:Treatment Failure
D001381:Azepines; C484278:N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide; D053829:Amyloid Precursor Protein Secretases; D000409:Alanine